Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mathew Wehbe (NPI 1619186368)

Field	Value
Entity Type	Individual
Organization	Mathew Wehbe
Address	411 Laurel Street
City	Des Moines
State	IA
ZIP	50314
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 21, 2007

Payer Source	Total Paid
Medicare	$1M
Medicaid	$0

Key Findings

This provider’s Medicare revenue footprint is concentrated and Medicare-dominant: lifetime Medicare revenue is $1M and there is no Medicaid billing on file, so the practice operates effectively as a single-payer (Medicare) biller in the available data. The precomputed top-3 Medicare codes account for 77.9% of total Medicare revenue, indicating a high revenue concentration in a small number of drugs/procedures.

Pembrolizumab (J9271) is the primary revenue driver, generating $688K and representing 67.7% of the provider’s Medicare revenue, which signals an immunotherapy-focused service line centered on checkpoint inhibitor infusions. Although J9271 accounts for the majority of revenue, the provider’s national ranking for this code is #614 of 1841 (66th percentile) and is described as "typical, unremarkable volume," so the practice is not an outlier or dominant national center for pembrolizumab despite the revenue concentration.

The second- and third-largest revenue contributors are J0897 (denosumab, $54K, 5.3%) and Q5115 (rituximab-abbs biosimilar, $49K, 4.8%), and together with J9271 make up the top-3 share used above. J0897 ranks #4543 of 10057 (54th percentile) and is similarly labeled "typical, unremarkable volume," which suggests routine use of bone-targeted agents alongside immunotherapy; Q5115 ranks #72 of 79 (8th percentile), indicating comparatively low volume among the small national group reporting that biosimilar.

The provider’s code mix is consistent with an outpatient medical oncology infusion practice: high-revenue biologic/immunotherapy codes (J9271, J0897, Q5115) are paired with multiple chemotherapy administration and infusion codes (96413, 96365, 96367, 96401, 96415, 96417) and supportive drugs (J1569 immune globulin, J0185 aprepitant). This pattern indicates on-site drug administration capacity and supportive care services rather than a practice driven primarily by office E/M visits or procedural surgery.

Office evaluation-and-management activity exists but contributes a small share of revenue: 99214 accounts for $35.7K (3.5% of Medicare revenue) with 401 claims and a national rank of #68885 of 479517 (86th percentile) described as "typical, unremarkable volume." The presence of higher-percentile E/M and infusion-administration ranks (for example 99214 at the 86th percentile and 96367 at the 85th percentile) suggests steady outpatient follow-up and infusion throughput that supports the high drug-revenue mix.

Several ancillary services and diagnostics are reported at above-median percentiles for national peers—examples include comprehensive metabolic panel (80053, 85th percentile), CBC (85025, 85th percentile), and routine venipuncture (36415, 84th percentile)—which aligns with oncology workflows that require ongoing lab monitoring. These lab and draw codes, while individually low revenue contributors, support the clinical infrastructure needed for frequent biologic and chemotherapy administration.

From a competitive standpoint, the provider appears to be a modest, established oncology participant rather than a dominant specialty hub: the practice has an NPI enumeration date of 2007-05-21 (~19 years ago), indicating long tenure, but most high-revenue codes are ranked in middle-to-upper percentiles and are labeled "typical, unremarkable volume," not indicating market dominance. The notable exception is Q5115’s low 8th percentile rank among 79 providers, which points to a specific product-level divergence from peers rather than broad competitive leadership.

For payers and network analysts, the practical implications are clear: the practice is heavily dependent on high-cost infused biologics—most prominently J9271—so contract design, utilization management, and site-of-care considerations should prioritize oncology drug management and infusion authorization pathways. Because there is no Medicaid activity on file, any Medicaid-network impact or negotiations would require outreach to confirm whether the provider treats Medicaid patients outside of billable Medicaid claims or is simply out of network for that payer.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

52 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	16,000	$40	$688K
J0897	Injection, denosumab, 1 mg	3,000	$20	$54K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	1,400	$40	$49K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,210	$40	$43.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	400	$90	$35.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	320	$90	$29.7K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	13,000	$1	$26K
99233	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	160	$90	$14.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	120	$120	$13.9K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	410	$20	$8.5K

Showing 1–10 of 52

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 52 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Mathew Wehbe — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

52 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	15	30	17,200	$40	$902.3K
J1569	11	10	2,680	$40	$133.6K
J0897	61	190	1,920	$20	$74.1K
Q5115	8	10	1,790	$30	$71.4K
J0881	9	10	15,520	$1	$43.2K
96413	23	80	210	$90	$24K
J0185	10	20	6,890	$1	$14.5K
99214	701	4,690	100	$70	$14.4K
99233	210	910	60	$90	$10.5K
99213	1,591	4,740	100	$50	$8K

Showing 1–10 of 52

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mathew Wehbe, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
Greater Regional Medical Center	IA	Critical Access Hospital	$0	$10M
Alegent Creighton Clinic	IA	Family Medicine Physician	$0	$9.6M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0

Nearby Providers

Other providers in the same ZIP code as Mathew Wehbe, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Broadlawns Medical Center	IA	General Acute Care Hospital	$0	$112.9M
Catholic Health Initiatives-iowa Corp	IA	General Acute Care Hospital	$0	$26.4M
Des Moines Independent Community School District	IA	Local Education Agency (LEA)	$0	$22.8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$14.1M
Broadlawns Medical Center	IA	Community/Behavioral Health Agency	$0	$13.2M
Mercy Clinics Inc	IA	Pediatric Adolescent Medicine Physician	$0	$10.7M
Des Moines River Physicians, LLC	IA	Emergency Medicine Physician	$0	$8.1M
Catholic Health Initiatives-iowa Corp	IA	Clinical Medical Laboratory	$0	$8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$7.9M
Vita Health Services	IA	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$7.5M

Mathew Wehbe — Billing Profile & Reimbursement Data

Sign up for Mathew Wehbe — Billing Profile & Reimbursement Data policy alerts

Mathew Wehbe — Billing Profile & Reimbursement Data

Sign up for Mathew Wehbe — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References